A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.
Also called NCT01242202
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 113 participants
- Sponsor
- Registry
-
NCT01242202
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01242202. Allocation not applicable; no masking; primary purpose treatment. Start 2010-10-21 (actual); primary completion 2012-05-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- ipragliflozin
- Intervention (Drug)
- alpha glucosidase inhibitor
- Lead sponsor
- Astellas Pharma Inc
Record details
- Record id
cardio:ct-nct01242202- Content hash
95d357a4352f50f18172af6d73943ea872f92a83150a1859a5496586d18a8d90